BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28373754)

  • 1. Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options.
    Yao S; Li J; Yao Z; Xu Y; Chu J; Zhang J; Jin S; Huang Y; Zhang J; Ma J; Zhao Y; Yang S; Liu Y
    Chin J Cancer Res; 2017 Feb; 29(1):57-65. PubMed ID: 28373754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Hui D; Proctor B; Donaldson J; Shenkier T; Hoskins P; Klasa R; Savage K; Chhanabhai M; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2010 Sep; 51(9):1658-67. PubMed ID: 20795790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
    Castillo JJ; Winer ES; Olszewski AJ
    Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse large B-cell lymphoma.
    Martelli M; Ferreri AJ; Agostinelli C; Di Rocco A; Pfreundschuh M; Pileri SA
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):146-71. PubMed ID: 23375551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
    Akkas BE; Vural GU
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era.
    Lu CS; Chen JH; Huang TC; Wu YY; Chang PY; Dai MS; Chen YC; Ho CL
    Leuk Lymphoma; 2015 Jul; 56(7):2047-55. PubMed ID: 25382616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
    Hwang HS; Yoon DH; Suh C; Huh J
    Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
    Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
    Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extranodal involvement of diffuse large B-cell lymphoma in the head and neck: An indicator of good prognosis.
    Lee DY; Kang K; Jung H; Park YM; Cho JG; Baek SK; Kwon SY; Jung KY; Woo JS
    Auris Nasus Larynx; 2019 Feb; 46(1):114-121. PubMed ID: 29861074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era.
    Jeong H; Cho H; Hong JY; Lee DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Suh C
    Front Oncol; 2022; 12():888925. PubMed ID: 35712469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 15. Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
    Lal A; Bhurgri Y; Vaziri I; Rizvi NB; Sadaf A; Sartajuddin S; Islam M; Kumar P; Adil S; Kakepoto GN; Masood N; Khurshed M; Alidina A
    Asian Pac J Cancer Prev; 2008; 9(3):453-8. PubMed ID: 19004134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
    Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
    Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.
    Gutiérrez-García G; Colomo L; Villamor N; Arenillas L; Martínez A; Cardesa T; García-Herrera A; Setoain X; Rodríguez S; Ghita G; Abrisqueta P; Giné E; Bosch F; Campo E; Montserrat E; López-Guillermo A
    Leuk Lymphoma; 2010 Jul; 51(7):1225-32. PubMed ID: 20497002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
    Ollila TA; Olszewski AJ
    Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.